{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:51:01Z","timestamp":1772164261765,"version":"3.50.1"},"reference-count":35,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of human cancers and is a promising marker for cancer detection. We investigated the feasibility of detecting aberrant DNA methylation in the urine and serum samples of renal cancer patients. We examined the tumor and the matched urine and serum DNA for aberrant methylation of nine gene promoters (CDH1, APC, MGMT, RASSF1A, GSTP1, p16, RAR-\u03b22, and ARF) from 17 patients with primary kidney cancer by quantitative fluorogenic real-time PCR. An additional 9 urine samples (total, 26) and 1 serum sample (total, 18) also were tested from renal cancer patients. Urine from 91 patients without genitourinary cancer and serum from 30 age-matched noncancer individuals were used as controls. Promoter hypermethylation of at least two of the genes studied was detected in 16 (94%) of 17 primary tumors. Aberrant methylation in urine and serum DNA generally was accompanied by methylation in the matched tumor samples. Urine samples from 91 control subjects without evidence of genitourinary cancer revealed no methylation of the MGMT, GSTP1, p16, and ARF genes, whereas methylation of RAR-\u03b22, RASSF1A, CDH1, APC, and TIMP3 was detected at low levels in a few control subjects. Overall, 23 (88%) of 26 urine samples and 12 (67%) of 18 serum samples from cancer patients were methylation positive for at least one of the genes tested. By combination of urine or serum analysis of renal cancer patients, hypermethylation was detected in 16 of 17 patients (94% sensitivity) with high specificity. Our findings suggest that promoter hypermethylation in urine or serum can be detected in the majority of renal cancer patients. This noninvasive high-throughput approach needs to be evaluated in large studies to assess its value in the early detection and surveillance of renal cancer.<\/jats:p>","DOI":"10.1158\/0008-5472.can-04-0799","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T18:41:49Z","timestamp":1127241709000},"page":"5511-5517","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer"],"prefix":"10.1158","volume":"64","author":[{"given":"Mohammad Obaidul","family":"Hoque","sequence":"first","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, Maryland, and"}]},{"given":"Shahnaz","family":"Begum","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland"}]},{"given":"Ozlem","family":"Topaloglu","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, Maryland, and"}]},{"given":"Carmen","family":"Jeronimo","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, Maryland, and"}]},{"given":"Elizabeth","family":"Mambo","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, Maryland, and"}]},{"given":"William H.","family":"Westra","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland"}]},{"given":"J. A.","family":"Califano","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, Maryland, and"}]},{"given":"David","family":"Sidransky","sequence":"additional","affiliation":[{"name":"1Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, Maryland, and"}]}],"member":"1086","published-online":{"date-parts":[[2004,8,2]]},"reference":[{"key":"2023011919511036700_B1","doi-asserted-by":"crossref","unstructured":"Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin, 50:\u20087-33, \u20082000.","DOI":"10.3322\/canjclin.50.1.7"},{"key":"2023011919511036700_B2","doi-asserted-by":"crossref","unstructured":"Pantuck AJ, Zisman A, Rauch MK, Belldegrun A. Incidental renal tumors. Urology, 56:\u2008190-6, \u20082000.","DOI":"10.1016\/S0090-4295(00)00655-5"},{"key":"2023011919511036700_B3","doi-asserted-by":"crossref","unstructured":"Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res, 72:\u2008141-96, \u20081998.","DOI":"10.1016\/S0065-230X(08)60702-2"},{"key":"2023011919511036700_B4","doi-asserted-by":"crossref","unstructured":"Bird A. The essentials of DNA methylation. Cell, 70:\u20085-8, \u20081992.","DOI":"10.1016\/0092-8674(92)90526-I"},{"key":"2023011919511036700_B5","doi-asserted-by":"crossref","unstructured":"Merlo A, Herman JG, Mao L, et al 5\u2032 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16\/CDKN2\/MTS1 in human cancers. Nat Med, 1:\u2008686-92, \u20081995.","DOI":"10.1038\/nm0795-686"},{"key":"2023011919511036700_B6","doi-asserted-by":"crossref","unstructured":"Herman JG, Umar A, Polyak K, et al Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA, 95:\u20086870-5, \u20081998.","DOI":"10.1073\/pnas.95.12.6870"},{"key":"2023011919511036700_B7","doi-asserted-by":"crossref","unstructured":"Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene, 17:\u20082413-7, \u20081998.","DOI":"10.1038\/sj.onc.1202178"},{"key":"2023011919511036700_B8","doi-asserted-by":"crossref","unstructured":"Romanenko A, Morell-Quadreny L, Lopez-Guerrero JA, et al P16INK4A and p15INK4B gene alteration associated with oxidative stress in renal cell carcinomas after the Chernobyl accident (pilot study). Diagn Mol Pathol, 11:\u2008163-9, \u20082002.","DOI":"10.1097\/00019606-200209000-00007"},{"key":"2023011919511036700_B9","unstructured":"Bachman KE, Herman JG, Corn PG, et al Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res, 59:\u2008798-802, \u20081999."},{"key":"2023011919511036700_B10","doi-asserted-by":"crossref","unstructured":"Nojima D, Nakajima K, Li LC, et al CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog, 32:\u200819-27, \u20082001.","DOI":"10.1002\/mc.1060"},{"key":"2023011919511036700_B11","doi-asserted-by":"crossref","unstructured":"Kawakami T, Okamoto K, Ogawa O, Okada Y. Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. Urology, 61:\u2008226-30, \u20082003.","DOI":"10.1016\/S0090-4295(02)02110-6"},{"key":"2023011919511036700_B12","doi-asserted-by":"crossref","unstructured":"Wagner KJ, Cooper WN, Grundy RG, et al Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms\u2019 tumour and colorectal cancer. Oncogene, 21:\u20087277-82, \u20082002.","DOI":"10.1038\/sj.onc.1205922"},{"key":"2023011919511036700_B13","unstructured":"Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res, 58:\u20084515-8, \u20081998."},{"key":"2023011919511036700_B14","doi-asserted-by":"crossref","unstructured":"Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet, 3:\u2008415-28, \u20082002.","DOI":"10.1038\/nrg816"},{"key":"2023011919511036700_B15","doi-asserted-by":"crossref","unstructured":"Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer, 3:\u2008253-66, \u20082003.","DOI":"10.1038\/nrc1045"},{"key":"2023011919511036700_B16","doi-asserted-by":"crossref","unstructured":"Ngan RK, Lau WH, Yip TT, et al Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann N Y Acad Sci, 945:\u200873-9, \u20082001.","DOI":"10.1111\/j.1749-6632.2001.tb03866.x"},{"key":"2023011919511036700_B17","doi-asserted-by":"crossref","unstructured":"Lo YM. Prognostic implication of pretreatment plasma\/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma. Biomed Pharmacother, 55:\u2008362-5, \u20082001.","DOI":"10.1016\/S0753-3322(01)00083-X"},{"key":"2023011919511036700_B18","doi-asserted-by":"crossref","unstructured":"Sidransky D, Von Eschenbach A, Tsai YC, et al Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252:\u2008706-9, \u20081991.","DOI":"10.1126\/science.2024123"},{"key":"2023011919511036700_B19","doi-asserted-by":"crossref","unstructured":"Eisenberger CF, Schoenberg M, Enger C, et al Diagnosis of renal cancer by molecular urinalysis. J Natl Cancer Inst, 91:\u20082028-32, \u20081999.","DOI":"10.1093\/jnci\/91.23.2028"},{"key":"2023011919511036700_B20","unstructured":"Gonzalgo ML, Eisenberger CF, Lee SM, et al Prognostic significance of preoperative molecular serum analysis in renal cancer. Clin Cancer Res, 8:\u20081878-81, \u20082002."},{"key":"2023011919511036700_B21","unstructured":"Sanchez-Cespedes M, Esteller M, Wu L, et al Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res, 60:\u2008892-5, \u20082000."},{"key":"2023011919511036700_B22","unstructured":"Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res, 59:\u200867-70, \u20081999."},{"key":"2023011919511036700_B23","doi-asserted-by":"crossref","unstructured":"Topaloglu O, Hoque MO, Tokumaru Y, et al Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res, 10:\u20082284-8, \u20082004.","DOI":"10.1158\/1078-0432.CCR-1111-3"},{"key":"2023011919511036700_B24","unstructured":"Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res, 63:\u20082216-22, \u20082003."},{"key":"2023011919511036700_B25","doi-asserted-by":"crossref","unstructured":"Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 93:\u20089821-6, \u20081996.","DOI":"10.1073\/pnas.93.18.9821"},{"key":"2023011919511036700_B26","unstructured":"Harden SV, Tokumaru Y, Westra WH, et al Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res, 9:\u20081370-5, \u20082003."},{"key":"2023011919511036700_B27","unstructured":"Eads CA, Lord RV, Wickramasinghe K, et al Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res, 61:\u20083410-8, \u20082001."},{"key":"2023011919511036700_B28","doi-asserted-by":"crossref","unstructured":"Eads CA, Danenberg KD, Kawakami K, et al MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res, 28:\u2008E32\u20082000.","DOI":"10.1093\/nar\/28.8.e32"},{"key":"2023011919511036700_B29","unstructured":"Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res, 59:\u20082302-6, \u20081999."},{"key":"2023011919511036700_B30","doi-asserted-by":"crossref","unstructured":"Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract, 181:\u2008125-43, \u20081986.","DOI":"10.1016\/S0344-0338(86)80001-2"},{"key":"2023011919511036700_B31","doi-asserted-by":"crossref","unstructured":"Gnarra JR, Tory K, Weng Y, et al Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet, 7:\u200885-90, \u20081994.","DOI":"10.1038\/ng0594-85"},{"key":"2023011919511036700_B32","doi-asserted-by":"crossref","unstructured":"Dreijerink K, Braga E, Kuzmin I, et al The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA, 98:\u20087504-9, \u20082001.","DOI":"10.1073\/pnas.131216298"},{"key":"2023011919511036700_B33","doi-asserted-by":"crossref","unstructured":"Kersting M, Friedl C, Kraus A, Behn M, Pankow W, Schuermann M. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol, 18:\u20083221-9, \u20082000.","DOI":"10.1200\/JCO.2000.18.18.3221"},{"key":"2023011919511036700_B34","unstructured":"Palmisano WA, Divine KK, Saccomanno G, et al Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res, 60:\u20085954-8, \u20082000."},{"key":"2023011919511036700_B35","unstructured":"Battagli C, Uzzo RG, Dulaimi E, et al Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res, 63:\u20088695-9, \u20082003."}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/15\/5511\/2516598\/5511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/64\/15\/5511\/2516598\/5511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T15:00:46Z","timestamp":1674140446000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/64\/15\/5511\/511511\/Quantitative-Detection-of-Promoter"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":35,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2004,8,2]]},"published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-04-0799","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6493929.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6493929","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22363866","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22363866.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,1]]}}}